GGrantIndex
← Leaderboards

Fuyuhiko Tamanoi

University Of California Los Angeles

$5,574,151
Attributed
$7,142,432
Total exposure
5
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $898K · FY200514
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14

Funding mix

By agency

NIH$7,142,432 · 5

By mechanism

R01$6,648,198 · 2
P30$484,234 · 1
R13$10,000 · 1
P01$0 · 1

Top collaborators

Most similar at University Of California Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Response

Research focus

ResponseInvestigationTumorPharmaceutical PreparationsAntineoplastic AgentsInstitutesMutantDrug Delivery SystemsResearch PersonnelPlaySignal TransductionGrantLaboratoriesPublic Health RelevanceDesignResearch StudyFundingSignal PathwayProteinsCellsCell LineCancer CellCancer TherapyPathway Interactions

Grant awards (30)

Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$380,516
R01 · FY2014 · CA · contact PI
Activating mutants of mTOR$327,750
R01 · FY2014 · CA · contact PI
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$22,823
R01 · FY2014 · CA · contact PI
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$369,346
R01 · FY2013 · CA · contact PI
Activating mutants of mTOR$317,614
R01 · FY2013 · CA · contact PI
Signal Transduction and Therapeutics$146,441
P30 · FY2013 · CA · contact PI
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$64,637
R01 · FY2013 · CA · contact PI
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$393,575
R01 · FY2012 · CA · contact PI
Activating mutants of mTOR$337,887
R01 · FY2012 · CA · contact PI
Signal Transduction and Therapeutics$110,840
P30 · FY2012 · CA · contact PI
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$45,234
R01 · FY2012 · CA · contact PI
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$394,252
R01 · FY2011 · CA · contact PI
Activating mutants of mTOR$337,887
R01 · FY2011 · CA · contact PI
Signal Transduction and Therapeutics$66,553
P30 · FY2011 · CA · contact PI
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs$420,659
R01 · FY2010 · CA · contact PI
Activating mutants of mTOR$348,337
R01 · FY2010 · CA · contact PI
Signal Transduction and Therapeutics$82,380
P30 · FY2010 · CA · contact PI
Rheb, a highly conserved farnesylated G-protein$106,858
R01 · FY2009 · CA · contact PI
Signal Transduction and Therapeutics$78,020
P30 · FY2009 · CA · contact PI
Rheb, a highly conserved farnesylated G-protein$338,645
R01 · FY2007 · CA · contact PI
Rheb, a highly conserved farnesylated G-protein$348,759
R01 · FY2006 · CA · contact PI
Rheb, a highly conserved farnesylated G-protein$357,152
R01 · FY2005 · CA
Rheb, a highly conserved farnesylated G-protein$355,284
R01 · FY2004 · CA
Rheb, a highly conserved farnesylated G-protein$353,043
R01 · FY2003 · CA
ISOPRENYLATION OF RAS AND OTHER PROTEINS IN YEAST$56,080
R01 · FY2003 · CA
ISOPRENYLATION OF RAS AND OTHER PROTEINS IN YEAST$333,540
R01 · FY2002 · CA
FASEB Summer Conference, July 20-25, 2002$10,000
R13 · FY2002 · CA
FARNESYLTRANSFERAE INHIBITOR ON PROSTATE AND BREAST CANCER$0
P01 · FY2002 · CA
ISOPRENYLATION OF RAS AND OTHER PROTEINS IN YEAST$323,826
R01 · FY2001 · CA
ISOPRENYLATION OF RAS AND OTHER PROTEINS IN YEAST$314,494
R01 · FY2000 · CA